1 false false false false false false false false false false true false false false false false false No description of principal activity 2025-02-01 Sage Accounts Production Advanced 2024 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 12329134 2025-02-01 2026-01-31 12329134 2026-01-31 12329134 2025-01-31 12329134 2024-02-01 2025-01-31 12329134 2025-01-31 12329134 2024-01-31 12329134 bus:Director1 2025-02-01 2026-01-31 12329134 core:WithinOneYear 2026-01-31 12329134 core:WithinOneYear 2025-01-31 12329134 core:ShareCapital 2026-01-31 12329134 core:ShareCapital 2025-01-31 12329134 core:SharePremium 2026-01-31 12329134 core:SharePremium 2025-01-31 12329134 core:RetainedEarningsAccumulatedLosses 2026-01-31 12329134 core:RetainedEarningsAccumulatedLosses 2025-01-31 12329134 bus:SmallEntities 2025-02-01 2026-01-31 12329134 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 12329134 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 12329134 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 12329134 bus:FullAccounts 2025-02-01 2026-01-31 12329134 core:KeyManagementPersonnel 2025-02-01 2026-01-31
COMPANY REGISTRATION NUMBER: 12329134

Senari Pharma Ltd

Filleted Unaudited Financial Statements

31 January 2026

Senari Pharma Ltd

Financial Statements

Year ended 31 January 2026

Contents | Page

Statement of financial position | 1

Notes to the financial statements | 2

Senari Pharma Ltd

Statement of Financial Position

31 January 2026

| 2026 | 2025
Note | £ | £ | £

Current assets

Debtors | 6 | 930 |  | 27,136
Cash at bank and in hand | 13,937 |  | 1,878
| -------- |  | --------
| 14,867 |  | 29,014

Creditors: amounts falling due within one year | 7 | 207,364 |  | 206,264
| --------- |  | ---------
Net current liabilities |  | 192,497 | 177,250
|  | --------- | ---------
Total assets less current liabilities |  | ( 192,497) | ( 177,250)
|  | --------- | ---------
Net liabilities |  | ( 192,497) | ( 177,250)
|  | --------- | ---------

Capital and reserves

Called up share capital |  | 169 | 169
Share premium account |  | 535,956 | 535,956
Profit and loss account |  | ( 728,622) | ( 713,375)
|  | --------- | ---------
Shareholders deficit |  | ( 192,497) | ( 177,250)
|  | --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 20 May 2026 , and are signed on behalf of the board by:

Dr S Dissanayake |
Director |

Company registration number: 12329134

Senari Pharma Ltd

Notes to the Financial Statements

Year ended 31 January 2026
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The Directors have considered the basis of the preparation of the accounts and is satisfied that the accounts should be prepared on a going concern basis. The Directors have confirmed that they will continue to provide financial support for the foreseeable future.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2025: 1 ).
5. Share capital
The company has issued 16,877 shares which at par gives a share capital total of £168.77. Due to the rounding factor the accounts have been prepared with, the balance sheet only shows £169 of share capital.
6. Debtors

| 2026 | 2025
| £ | £
Other debtors | 930 | 27,136
| ---- | --------

7. Creditors: amounts falling due within one year

| 2026 | 2025
| £ | £
Trade creditors | 876 | 11,777
Other creditors | 206,488 | 194,487
| --------- | ---------
| 207,364 | 206,264
| --------- | ---------

8. Related party transactions
At the year end the company owed the Director £201,438 (2025: £189,438).